Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal

Biotech company Illumina pushes back against Carl Icahn’s proxy fight over .1 billion Grail deal


Carl Icahn

Adam Jeffery | CNBC

Biotech company Illumina pushed back Monday against Carl Icahn’s proxy fight over the company’s acquisition of cancer test developer Grail, saying the activist investor’s board nominees “do not add value.” 

The San Diego-based DNA sequencing company released its latest response to Icahn’s sharp criticism of the $7.1 billion deal it completed in 2021, saying it’s committed to maximizing shareholder value as it works with antitrust regulators to “define GRAIL’s path forward as expeditiously as possible.”

Icahn, who owns a 1.4% stake in Illumina, sent an open letter to the company’s shareholders last week saying the DNA sequencing company paid too much for Grail and completed the “reckless” deal without getting European antitrust regulatory approval. He claimed those actions have wiped out $50 billion in Illumina’s market value and “clearly shows that shareholders have lost faith in Illumina’s management team and board of directors.” Grail is based in Menlo Park, Calif.

Icahn also announced his intentions to nominate three members to Illumina’s board during the company’s annual meeting of shareholders due to fears that the board “will pursue GRAIL until the end of time without regard to the amount of value destruction they leave in their wake.”

“To paraphrase William Shakespeare’s Hamlet, something is rotten in the state of Illumina,” Icahn wrote. Illumina’s stock, which has lost more than half its value from an August 2021 peak, jumped 17% after Icahn released his letter. 

In its response Monday, Illumina underscored its efforts to work through ongoing regulatory opposition.

Last year, the European Commission blocked the acquisition over concerns that it would hurt consumer choice and unveiled details of a planned order that would force Illumina to unwind the deal. That could result in a fine of up to 10% of Illumina’s annual revenues, which hit more than $4.5 billion last year.

Illumina said it has challenged the European Commission, arguing the agency lacks jurisdiction to block the merger between the two U.S. companies. A final decision is expected in late 2023 or early 2024, the company noted. Illumina said winning a jurisdictional appeal would eliminate any potential fine and “gives the greatest optionality for Illumina to maximize value for shareholders.”

The company also claimed Icahn recognizes the value of Grail to shareholders, pointing to a CNBC interview last week where Icahn referred to Grail as Illumina’s “best equipment.” Illumina added that the billionaire investor acknowledged that he doesn’t understand the regulatory process and has not offered ideas for a “rapid resolution” for Grail. 

“Icahn has no ability to accelerate the legal and regulatory processes and neither do his nominees,” Illumina said. 

The company added it has interviewed each of Icahn’s nominees and found they “lacked relevant skills and experience.” That includes Vincent Intrieri, the founder and CEO of VDA Capital Management who was previously employed by Icahn. It also includes General Counsel of Icahn Enterprises Jesse Lynn and Andrew Teno, a portfolio manager at Icahn Capital LP, an entity where Icahn manages investment funds.

Illumina touted Grail in its release, saying it has “tremendous long-term value creation potential.” Grail claims to offer the only commercially available early screening test that can detect more than 50 types of cancers through a single blood draw, Illumina said. The test generated $55 million of revenue in 2022 and is slated to rake in up to $110 million this year, according to Illumina.

The U.K.’s National Health Service is researching the test in a study with 140,000 participants, Illumina added. If the study is successful, the agency expects to test one million people in the U.K. in 2024.



Source

‘You’ll be back’: Arnold Schwarzenegger on the most important move to make to stay healthy aging into 50s, 60s and beyond
Health

‘You’ll be back’: Arnold Schwarzenegger on the most important move to make to stay healthy aging into 50s, 60s and beyond

On film, Arnold Schwarzenegger has been tough to take down. But in real life, the actor and former governor of California has had his share of health issues that required surgery and replacement parts as he has aged. Through it all, he continues to work out — a daily regimen that includes a bicycle for […]

Read More
FDA outlines stricter Covid vaccine booster approval standards for healthy people
Health

FDA outlines stricter Covid vaccine booster approval standards for healthy people

Brandon Guerrero, 34, of Compton, receives both a flu and COVID-19 vaccine at CVS in Huntington Park on August 28, 2024. Christina House | Los Angeles Times | Getty Images The Food and Drug Administration on Tuesday outlined new regulatory guidance for future Covid-19 vaccine boosters, setting stricter approval standards for healthy Americans.  The FDA […]

Read More
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Health

Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly

A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.  Tom Little | Reuters Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker on Friday abruptly announced that […]

Read More